INDEX

Chapter No.	Contents	Page No.
1.	**Introduction**	**1-8**
1.1.	Introduction	1
1.2.	Objectives of work	6
	Reference	7-8
2.	**Literature Review**	**9-42**
2.1.	What is Cancer?	9
2.2.	Angiogenesis	9
2.3.	Tumour angiogenesis: Therapeutic implications	11
2.4.	Vascular targeting therapy	11
2.5.	Drug targeting to solid tumors	12
2.6.	Passive targeting	12
2.7.	Active targeting	13
2.8.	Cancer cell targeting	14
2.9.	Tumor endothelial cell targeting	15
2.10.	Neuropilins	17
2.11.	Immunoliposomes	20
2.12.	Actively tumor targeted liposomes under preclinical and clinical trials	23
2.13.	Recent activities of immunoliposome preparation	23
2.13.1.	Single chain antibodies	23
2.13.2.	Affibodies as targeting ligands	25
2.14.	Docetaxel	31
2.14.1.	Introduction	31
2.14.2.	Description	31
2.14.3.	Physicochemical properties	31
2.14.4.	Physicochemical stability	32
2.14.5.	Clinical pharmacology	32
2.14.6.	Pharmacokinetics	32
2.14.7.	Toxicology	32
2.14.8.	Indication and usage	33
2.14.9.	Dosage and administration	33
2.14.10.	Analytical methods	33
	Reference	34-42
3.	**Analytical Methods**	**43-62**
3.1.	Introduction	43
3.2.	Experimental	43
3.3.	Methods	43
3.3.1.	Estimation of docetaxel by UV-visible spectrophotometer	43
3.3.2.	Estimation of docetaxel and their impurities by RP-HPLC method	43
3.3.3.	Estimation of total phospholipid content by Stewart method	44
3.3.4.	Estimation of plasma proteins (BCA protein estimation method)	44
3.3.5	Estimation of cell lysate protein by Bradford method	46
3.3.6.	Estimation of cysteine by Ellman's assay	47
3.4.	Results and Discussion	48

3.4.1.	Estimation of docetaxel by UV-visible spectrophotometer	48
3.4.2.	Estimation of docetaxel and its impurities by RP-HPLC method	50
3.4.2.1	Estimation of docetaxel	51
3.4.2.2	Estimation of 7-epidocetaxel	52
3.4.2.3	Estimation of 10-oxo-7-epidocetaxel	54
3.4.3	Estimation of total phospholipid concentration by Stewart colorimetric method	55
3.4.4	Estimation of bovine serum albumin (BSA) by Bicinchonic acid (BCA) method	57
3.4.5	Estimation of cell lysates proteins using Bradford method	58
3.4.6	Estimation of cysteine by Ellman's assay	59
	Reference	61-62
4.	**Preparation of Conventional Liposomes**	**63-86**
4.1.	Introduction	63
4.2.	Materials and Methods	64
4.3.	Preparation of liposomes by thin film hydration method	65
4.3.1.	Optimization of formulation variables by applying 3^3 factorial design	65
4.3.2.	Optimization of process variables	66
4.3.3.	Optimization of cholesterol concentration	66
4.3.4.	Characterization of prepared liposomes	66
4.3.4.1.	Docetaxel content	66
4.3.4.2.	Particle size analysis	67
4.3.4.3.	The zeta (ç) potential analysis	67
4.4.	Preparation of impurity free docetaxel liposomes	67
4.4.1.	Introduction	67
4.4.2.	Identification of docetaxel impurities formed at different temperature	69
4.4.3.	3^3 factorial design-2	69
4.4.4.	Comparison of different organic acids as degradation inhibitors	69
4.5.	Results and Discussion	70
4.5.1.	Preparation of conventional liposomes	70
4.5.2.	Optimization of process variables	73
4.5.3.	Optimization of cholesterol concentration	73
4.5.4.	Preparation of impurity free liposomes	75
4.5.4.1.	Identification of docetaxel impurities in liposomes	75
4.5.4.2.	3^3 factorial design	77
4.5.4.3.	Comparison of different organic acids as degradation inhibitors	81
	Reference	84-86
5.	**Preparation of PEGylated and Functionalised PEGylated Liposomes**	**87-106**
5.1.	Introduction	87
5.2.	Materials and Methods	88
5.3.	Preparation of PEGylated liposomes	88
5.3.1.	Sodium sulphate induced flocculation	88
5.3.2.	*In vitro* serum protein adsorption (opsonisation study)	88

5.4.	Preparation of functionalised pegylated liposomes	90
5.4.1.	Introduction	90
5.4.2.	Identification of maleimide functional group of DSPE-$mPEG_{2000}$-maleimide	90
5.4.3.	Preparation of functionalized PEGylated liposomes	90
5.4.4.	Confirmation of functional lipid insertion over PEGylated liposomes	91
5.5.	Results and Discussion	91
5.5.1.	Preparation of PEGylated liposomes.....	91
5.5.2.	Sodium sulphate induced flocculation	93
5.5.3.	*In vitro* serum protein adsorption (opsonisation study)	95
5.5.4.	Preparation of functionalised pegylated liposomes	100
5.5.5.	Confirmation of presence of maleimide groups over PEGylated liposomes	102
	Reference	104-106
6.	**Preparation of Immunoliposomes	**107-130**
6.1.	Introduction	107
6.2.	Materials and Methods	111
6.3.	Modification of antibody	112
6.3.1.	Preparation and purification of $F(ab')_2$ fragments of Anti-neuropilin-1 antibody	112
6.3.2.	Reduction of $F(ab')_2$ into Fab'-SH	113
6.4.	Preparation of immunoliposomes	113
6.5.	Characterization	114
6.5.1.	SDS-PAGE analysis of $F(ab')_2$, Fab'-SH and immunoliposomes	114
6.5.2.	Silver staining method	114
6.5.3.	Ellman's assay to confirm the presence of –SH groups on Fab' fragments	116
6.5.4.	Determination of concentration Fab' fragments present in unknown solution and over liposomal surface	116
6.5.5.	Immunoreactivity of prepared Fab' fragments and immunoliposomes	117
6.6.	Results and Discussion	117
6.6.1.	SDS-PAGE analysis of modified antibody and immunoliposomes	117
6.6.2.	Determination of presence of sulfhydryl groups on Fab' fragments	120
6.6.3.	Preparation of immunoliposomes	121
6.6.4.	Determination of immunoreactivity of prepared Fab' fragment and immunoliposomes	122
	Reference	128-130
7.	**Determination of Neuropilin-1 Receptor Expression**	**131-142**
7.1.	Introduction	131
7.2.	Materials and Methods	132
7.3.	Determination of neuropilin-1 expression	133
7.3.1.	Western blotting analysis	133
7.3.2.	FACS analysis	137
7.3.3.	Confocal microscopy	137
7.4.	Results and Discussion	137

	Reference	141-142
8.	**Characterization of PEGylated liposomes and Immunoliposomes**	**143-190**
8.1.	Morphology study	143
8.1.1.	Olympus microscopy	143
8.1.2.	Transmission electron microscope (TEM)	143
8.2.	FTIR study	143
8.3.	Differential scanning calorimetry	143
8.4.	Controlled drug release	143
8.5.	Suspension stability study	144
8.6.	*In vitro* cytotoxicity assay	144
8.7.	Cell uptake study	145
8.7.1.	Preparation of 6-coumarin loaded liposomes	145
8.7.2.	Cell uptake study using FACS	145
8.7.3.	Cell uptake study using confocal microscopy	145
8.7.4.	Live cell uptake imaging by confocal microscope	145
8.8.	Anti-metastatic activity by wound scratch assay	145
8.9.	Gelatin zymography	146
8.9.1.	Introduction	146
8.9.2.	Method	148
8.10.	Apoptosis study	149
8.10.1.	Using FACS	149
8.10.2.	Using EB/AO staining	149
8.11.	Cell cycle analysis	149
8.12.	Results and Discussion	149
8.12.1.	Morphology study	149
8.12.2.	FTIR study	151
8.12.3.	Differential Scanning Calorimetry	152
8.12.4.	Controlled drug release	154
8.12.5.	Suspension stability study	159
8.12.6.	*In vitro* cytotoxicity assay	161
8.12.7.	Cell uptake study	165
8.12.7.1.	Cell uptake study using FACS	165
8.12.7.2.	Cell uptake study using confocal microscopy	169
8.12.7.3.	Live cell uptake imaging by confocal microscope	169
8.12.8.	Anti-metastatic activity by wound scratch assay	172
8.12.9.	Gelatin zymography	175
8.12.10.	Apoptosis assay	177
8.12.10.1.	Using FACS	177
8.12.10.2.	Using EB/AO staining	180
8.12.11.	Cell cycle analysis	182
	Reference	187-190
9.	***In vivo* Tumor Regression and Angiogenesis Study**	**191-204**
9.1.	Introduction	191
9.2.	Tumor regression and angiogenesis study	192
9.3.	Results and Discussion	193
9.3.1.	Tumor regression performance of formulations	193
9.3.2.	Anti-angiogenesis performance of formulations	198
	Reference	202-204
10.	***In vitro* and *In vivo* Characterization of Docetaxel and its Impurities**	**205-250**
10.1.	Introduction	205
10.2.	Materials and methods	207

10.3.	Preparation of docetaxel impurities formulation	208
10.4.	*In vitro* cytotoxicity assay	208
10.5	Anti-metastatic activity by wound scratch assay	208
10.6	Gelatin zymography	209
10.7.	Apoptosis assay using FACS	209
10.8.	Cell cycle analysis	209
10.9.	Acute toxicity study	210
10.10	Therapeutic study of 10-oxo-7-epidocetaxel	210
10.11.	Results and Discussion	211
10.11.1.	Stability of docetaxel impurities	211
10.11.2.	*In vitro* cytotoxicity assay	214
10.11.3.	Anti-metastatic activity by wound scratch assay	217
10.11.4.	Gelatin zymography	220
10.11.5.	Apoptosis assay using FACS	222
10.11.6.	Cell cycle analysis	226
10.11.7.	Acute toxicity study	241
10.11.8.	Therapeutic study of 10-oxo-7-epidocetaxel	245
	Reference	249-250
11.	**Summary and Conclusions	**251-261**